{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:53:54Z","timestamp":1759366434021,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.revmed.2023.11.002","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T19:38:36Z","timestamp":1700249916000},"page":"109-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioth\u00e9rapies cibl\u00e9es\u00a0: nouveaut\u00e9s dans la scl\u00e9rodermie syst\u00e9mique\u00a0!"],"prefix":"10.1016","volume":"45","author":[{"given":"B.","family":"Chaigne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mouthon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2023.11.002_bib0215","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","author":"Denton","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.revmed.2023.11.002_bib0220","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/rheumatology\/keh253","article-title":"Prevalence of systemic sclerosis in a French multi-ethnic county","volume":"43","author":"Le Guern","year":"2004","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.revmed.2023.11.002_bib0225","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.semarthrit.2012.10.001","article-title":"Estimating the prevalence of systemic sclerosis in the Lorraine region, France, by the capture-recapture method","volume":"42","author":"El Adssi","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2023.11.002_bib0230","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.autrev.2014.08.029","article-title":"Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients\u2019 population and review of the literature","volume":"13","author":"Ferri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2023.11.002_bib0235","first-page":"1207","article-title":"Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6\u00a0by fibroblasts cultured from affected skin sites of patients with scleroderma","volume":"19","author":"Feghali","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2023.11.002_bib0240","article-title":"Scleroderma peripheral B lymphocytes secrete interleukin-6\u00a0and TGF-\u03b2 and activate fibroblasts","author":"Dumoitier","year":"2016","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.revmed.2023.11.002_bib0245","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/ar4672","article-title":"Targeting IL-6\u00a0by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis","volume":"16","author":"Desallais","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2023.11.002_bib0250","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.revmed.2023.11.002_bib0255","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.revmed.2023.11.002_bib0260","unstructured":"Scl\u00e9rodermie Syst\u00e9mique. Haute Aut Sant\u00e9 n.d. https:\/\/www.has-sante.fr\/jcms\/c_717292\/fr\/sclerodermie-systemique (accessed August 6, 2019)."},{"key":"10.1016\/j.revmed.2023.11.002_bib0265","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/rheumatology\/keac300","article-title":"Biological and clinical insights from a randomized phase 2\u00a0study of an anti-oncostatin M monoclonal antibody in systemic sclerosis","volume":"62","author":"Denton","year":"2022","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.revmed.2023.11.002_bib0270","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.11.002_bib0275","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2022-eular.2519","article-title":"Pos0881\u00a0Efficacy and Safety of Subcutaneous Brodalumab, a Fully Human Anti\u2013Il-17ra Monoclonal Antibody, for Systemic Sclerosis with Moderate-to-Severe Skin Thickening: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Phase 3\u00a0Study","volume":"81","author":"Fukasawa","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.11.002_bib0280","doi-asserted-by":"crossref","first-page":"e159566","DOI":"10.1172\/jci.insight.159566","article-title":"Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial","volume":"7","author":"Khanna","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.revmed.2023.11.002_bib0285","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00296-021-04956-7","article-title":"Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound","volume":"41","author":"Karalilova","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.revmed.2023.11.002_bib0290","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00296-020-04767-2","article-title":"Successful use of tofacitinib in the treatment of diffuse systemic sclerosis and axial spondyloarthritis: a case-based review","volume":"41","author":"Kyriakou","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.revmed.2023.11.002_bib0295","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1093\/rheumatology\/keaa613","article-title":"Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis","volume":"60","author":"You","year":"2021","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.revmed.2023.11.002_bib0300","article-title":"Abatacept in Early Diffuse Cutaneous Systemic Sclerosis - Results of a Phase 2\u00a0Investigator-Initiated, Multicenter, Double-Blind Randomized Placebo-Controlled Trial","author":"Khanna","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.revmed.2023.11.002_bib0305","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.revmed.2023.11.002_bib0310","article-title":"Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial","author":"Gordon","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.revmed.2023.11.002_bib0315","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2023.11.002_bib0320","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/ard-2022-222564","article-title":"Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON","volume":"81","author":"Allanore","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.11.002_bib0325","doi-asserted-by":"crossref","first-page":"e002859","DOI":"10.1136\/rmdopen-2022-002859","article-title":"Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression","volume":"9","author":"Khanna","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.revmed.2023.11.002_bib0330","article-title":"Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial","author":"Denton","year":"2022","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.revmed.2023.11.002_bib0335","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/acr2.11483","article-title":"Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100\u00a0Weeks: Data From a Randomized Controlled Trial","volume":"4","author":"Assassi","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.revmed.2023.11.002_bib0340","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.revmed.2023.11.002_bib0345","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3899\/jrheum.161040","article-title":"Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study","volume":"45","author":"Hsu","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2023.11.002_bib0350","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3899\/jrheum.191365","article-title":"STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease","volume":"48","author":"Khanna","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2023.11.002_bib0355","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/art.40242","article-title":"Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study","volume":"69","author":"Denton","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.revmed.2023.11.002_bib0360","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/rheumatology\/keac426","article-title":"A phase 2\u00a0trial investigating the effects of the angiotensin II type 2\u00a0receptor agonist C21\u00a0in systemic sclerosis-related Raynaud's","volume":"62","author":"Herrick","year":"2023","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.revmed.2023.11.002_bib0365","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13075-022-02818-6","article-title":"Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial","volume":"24","author":"Stern","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2023.11.002_bib0370","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.revmed.2023.11.002_bib0375","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2020-219100","article-title":"New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis","volume":"80","author":"Khanna","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.11.002_bib0380","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/annrheumdis-2021-220702","article-title":"Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire","volume":"81","author":"Becker","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.11.002_bib0385","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.revmed.2023.11.002_bib0390","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.42510","article-title":"Efficacy and Safety of Lenabasum, a Cannabinoid Type 2\u00a0Receptor Agonist, in a Phase 3\u00a0Randomized Trial in Diffuse Cutaneous Systemic Sclerosis","volume":"75","author":"Spiera","year":"2023","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.revmed.2023.11.002_bib0395","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.revmed.2023.11.002_bib0400","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human anti-interferon-\u03b1 receptor monoclonal antibody MEDI-546\u00a0in subjects with systemic sclerosis: a phase 1, multicenter, open label study","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"10.1016\/j.revmed.2023.11.002_bib0405","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.rmed.2016.09.011","article-title":"RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis","volume":"122","author":"Distler","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.revmed.2023.11.002_bib0410","doi-asserted-by":"crossref","first-page":"SI125","DOI":"10.1093\/rheumatology\/keac433","article-title":"Soluble guanylate cyclase stimulation fosters angiogenesis and blunts myofibroblast-like features of systemic sclerosis endothelial cells","volume":"62","author":"Romano","year":"2023","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.revmed.2023.11.002_bib0415","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13075-021-02513-y","article-title":"Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis","volume":"23","author":"Yamamoto","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2023.11.002_bib0210","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/annrheumdis-2014-206809","article-title":"Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies","volume":"74","author":"Dees","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866323012468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866323012468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:47:06Z","timestamp":1759337226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866323012468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0248866323012468"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2023.11.002","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioth\u00e9rapies cibl\u00e9es\u00a0: nouveaut\u00e9s dans la scl\u00e9rodermie syst\u00e9mique\u00a0!","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2023.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}